Loading condition report…
Loading condition report…
A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
Evidence at a glance
Open any number to go directly to the underlying records.
The report maps directly scoped documents, study registrations, formulations and exact source-reported evidence. Efficacy, treatment and safety conclusions remain unvalidated. Every item links back to preserved source material. Study registrations and dose records describe what researchers reported or planned; they are not treatment advice or proof that an intervention works.
Condition scope
Subtype counts can overlap because one article may discuss more than one condition.
Research map
These are document-level associations. The first group has study-registration or regulatory context; neither group proves efficacy or clinical use.
Chronic migraine
registered studies · not a treatment claimChronic migraine · Migraine with aura
registered studies · not a treatment claimChronic migraine · Episodic migraine
document association · not a treatment claimHow treatment was studied
Routes and dose values below describe registered or published research. They are not prescribing instructions.
What researchers planned or recorded in trial registrations.
No exact dose descriptions were present in this frozen report snapshot.
How the intervention was described as being given in registered studies.
Open a route to see its registrations. A study may appear under more than one route.
Source-backed observations from readable publications.
Systematic review: researchers use a documented method to find, select and assess all relevant studies for a specific question.
Meta-analysis: when the studies are sufficiently comparable, their numerical results are combined statistically.
These methods can provide a broader view than one study, but their reliability still depends on the quality and similarity of the included evidence. They do not automatically prove that a treatment works.
No publication-level dosing evidence is available in this frozen snapshot.
How the research was designed
These labels describe the registered study design—not whether the treatment worked. A study can use several methods, so categories may overlap. Protocol categories are deterministic title/type matches and use a multi-label taxonomy. Filters preserve every matching tag while each registration is shown once. Registration is not a result.
Showing 12 of 12 unique registrations. 12 pattern memberships are preserved as badges; counts may overlap.
Primary working hypothesis is that NON-responders to mAbs bear a dysfunction of the endocannabidiome system (eCBome), as suggested by pre-clinical and clinical data by our group. They will be identified as patients showing a reduction of monthly migraine days \< 50% after three months of treatment.
Open study recordAim of the study was to assess a potential dysfunction of the endocannabidiome system (eCBome) in migraine patients. Migraine patients who will undergo preventive therapy with monoclonal antibodies directed against the calcitonin gene related peptide (mAbs) will be evaluated through a deep phenotyping of peripheral neurochemical biomarkers (eCBome, neuropeptides, cytokines and kynurenine levels, and microRNAs expression).
Open study recordResearch frequency
Counts use the directly scoped, rights-cleared article snapshot. The current year is partial.
Registries
A registration describes the protocol. When posted, source-reported outcomes and safety are preserved on the local Study page.
Browse the complete filtered study catalog →
Showing 12 of 14 directly scoped registrations.
75 enrolled
Open study record80 enrolled
Open study record30 enrolled
Open study record45 enrolled
Open study record100 enrolled
Open study record92 enrolled
Open study record31 enrolled
Open study record0 enrolled
Open study record152 enrolled
Open study record20 enrolled
Open study record72 enrolled
Open study record30 enrolled
Open study recordSupporting evidence and regulatory context
Available items are locally preserved, frozen candidates. Funding and related research remain unavailable until a complete relevance-policy-v2 section is frozen; unavailable safety linkage is never presented as zero. Source metadata and safety reports are not efficacy or causality claims.
Frozen 14/09/2026 · 2,492 records · source sync still in progress
PROJECT NARRATIVE - RELEVANCE TO PUBLIC HEALTH Migraine represents a significant burden to society. The proposed experiments will establish whether a cannabis extract of cannabidiol and Δ9-tetrahydrocannabinol, alone or in predefined combinations designed to optimize efficacy and minimize adverse effects, could be developed into valid FDA- approved therapeutics to treat migraine. FDA-approved cannabis-based drugs for migraine would provide an excellent alternative for the part of the patient population that doesn’t respond to existing treatments, as well as an alternative to the use of unregulated or illicit cannabis.
Narrative This SBIR focuses on developing an optimized combination CBD and THC fixed-dose therapeutic for FDA approval to treat migraine with and without aura, the second most debilitating disease worldwide. This new product will offer an optimally safe and effective cannabinoid combination to treat migraine under FDA oversight, within U.S. federal and international healthcare systems, and enabling careful physician led disease management as an alternative to self-medication with unregulated cannabis.
Narrative This SBIR focuses on developing an optimized combination CBD and THC fixed-dose therapeutic for FDA approval to treat migraine with and without aura, the second most debilitating disease worldwide. This new product will offer an optimally safe and effective cannabinoid combination to treat migraine under FDA oversight, within U.S. federal and international healthcare systems, and enabling careful physician led disease management as an alternative to self-medication with unregulated cannabis.
Unavailable. Governed relevance linkage is not ready for this frozen snapshot; no absence of records is inferred.
FAERS package linkage is unavailable; zero reports must not be inferred until exact governed medicine links are ready.
Regulatory records
Active ingredient: cannabis, ACETIC ACID, ACONITUM NAPELLUS, ACTIVATED CHARCOAL, ALLIUM CEPA WHOLE, ALOE, ANACARDIUM OCCIDENTALE FRUIT, APIS MELLIFERA VENOM, ARNICA MONTANA, ARSENIC ACID, ASAFETIDA, CALCIUM SULFATE, EPINEPHRINE, WORMWOOD, ALUMINUM OXIDE, ANTIMONY POTASSIUM TARTRATE, ARSENIC TRIIODIDE, ATROPA BELLADONNA, BERBERIS VULGARIS ROOT BARK, BRYONIA ALBA ROOT, CANNABIS SATIVA SUBSP. INDICA TOP, COPPER, GOLD, SILVER CHLORIDE, SOLANUM DULCAMARA TOP, BAMBUSA BAMBOS WHOLE, BAPTISIA TINCTORIA, BAPTISIA TINCTORIA ROOT, CANNABIS SATIVA SUBSP. SATIVA FLOWERING TOP, CARBO ANIMALIS, EUPHRASIA STRICTA, FERRUM PHOSPHORICUM, MERCURIUS SOLUBILIS, ARABICA COFFEE BEAN, ASTACUS ASTACUS, BARIUM CARBONATE, BROMINE, CALCIUM CARBONATE, CASEIN, CAULOPHYLLUM THALICTROIDES ROOT, FELIS CATUS DANDER, GELSEMIUM SEMPERVIRENS ROOT, GRAPHITE, PHOSPHORUS, PULSATILLA VULGARIS, BARIUM CHLORIDE DIHYDRATE, CAUSTICUM, CICUTA VIROSA WHOLE, CINCHONA OFFICINALIS BARK, CITRULLUS COLOCYNTHIS FRUIT PULP, HELLEBORUS FOETIDUS ROOT, HYPERICUM PERFORATUM, OYSTER SHELL CALCIUM CARBONATE, CRUDE, SODIUM PHOSPHATE, SPONGIA OFFICINALIS SKELETON, ROASTED, STRYCHNOS NUX-VOMICA SEED, ANAMIRTA COCCULUS SEED, ARTEMISIA CINA PRE-FLOWERING TOP, CALCIUM PHOSPHATE, CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS, CALCIUM SULFATE ANHYDROUS, CALCIUM SULFIDE, CALENDULA OFFICINALIS FLOWERING TOP, CARBON DISULFIDE, CHELIDONIUM MAJUS, CORN, HOUSE DUST, IPECAC, OPIUM, POTASSIUM CARBONATE, POTASSIUM DICHROMATE, RUMEX CRISPUS ROOT, TIN, CAPSICUM, COLCHICUM AUTUMNALE BULB, CONIUM MACULATUM FLOWERING TOP, DERMATOPHAGOIDES FARINAE, DROSERA ROTUNDIFOLIA, EUPATORIUM PERFOLIATUM FLOWERING TOP, FD&C YELLOW NO. 5, HYDRASTIS CANADENSIS WHOLE, HYOSCYAMUS NIGER, IRIS VERSICOLOR ROOT, LEAD, LOBARIA PULMONARIA, LYCOPODIUM CLAVATUM SPORE, MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE, MERCURY, VERATRUM ALBUM ROOT, CANIS LUPUS FAMILIARIS MILK, D&C YELLOW NO. 11, DERMATOPHAGOIDES PTERONYSSINUS, GUAIACUM OFFICINALE RESIN, PODOPHYLLUM, SCHOENOCAULON OFFICINALE SEED, SODIUM SULFATE, STRYCHNOS IGNATII SEED, WYETHIA HELENIOIDES ROOT, AMARANTH, CHLORAL HYDRATE, HUMAN DANDER, LEDUM PALUSTRE TWIG, LILIUM LANCIFOLIUM WHOLE FLOWERING, MENTHA PIPERITA, POTASSIUM IODIDE, SEPIA OFFICINALIS JUICE, TANACETUM PARTHENIUM, TOXICODENDRON PUBESCENS LEAF, COPAIFERA OFFICINALIS RESIN, FD&C YELLOW NO. 6, FERROUS IODIDE, HISTAMINE DIHYDROCHLORIDE, HYDROFLUORIC ACID, INFLUENZA A VIRUS, IODINE, KEROSENE, LYCOPODIUM CLAVATUM WHOLE, RANCID BEEF, RUTA GRAVEOLENS FLOWERING TOP, SILICON DIOXIDE, CERVUS ELAPHUS HORN OIL, CORTISONE ACETATE, DELPHINIUM STAPHISAGRIA SEED, GONORRHEAL URETHRAL SECRETION HUMAN, INFLUENZA B VIRUS, MAGNESIUM CHLORIDE, NITRIC ACID, SODIUM CHLORIDE, SODIUM NITRITE, AGROSTIS CAPILLARIS POLLEN, LACHESIS MUTA VENOM, NAJA NAJA VENOM, RHEUM OFFICINALE ROOT, SODIUM BENZOATE, ALOPECURUS PRATENSIS POLLEN, PHOSPHORIC ACID, PROPYLPARABEN, URTICA URENS, ANTHOXANTHUM ODORATUM POLLEN, CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE, METHYLPARABEN, SCABIES LESION LYSATE (HUMAN), SULFUR, ARRHENATHERUM ELATIUS POLLEN, PHYTOLACCA AMERICANA ROOT, SANGUINARIA CANADENSIS ROOT, BROMUS COMMUTATUS POLLEN, SAMBUCUS CANADENSIS FLOWERING TOP, SENECIO VULGARIS, THUJA OCCIDENTALIS LEAFY TWIG, CYNOSURUS CRISTATUS POLLEN, PEANUT, SAW PALMETTO, VALERIAN, DACTYLIS GLOMERATA POLLEN, DATURA STRAMONIUM, ENGLISH WALNUT, ALMOND, FESTUCA PRATENSIS POLLEN, PACKERA AUREA, HOLCUS LANATUS POLLEN, MODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE), LOLIUM PERENNE POLLEN, MONOSODIUM GLUTAMATE, PHLEUM PRATENSE POLLEN, ALNUS GLUTINOSA POLLEN, BETULA PENDULA POLLEN, SACCHARIN, CORYLUS AVELLANA POLLEN, SOYBEAN, FAGUS SYLVATICA POLLEN, STRAWBERRY, FRAXINUS EXCELSIOR POLLEN, PLATANUS X ACERIFOLIA POLLEN, WHEAT GLUTEN, EGG, POPULUS TREMULA POLLEN, QUERCUS ROBUR POLLEN, SALIX ALBA POLLEN, AMBROSIA ARTEMISIIFOLIA POLLEN, ARTEMISIA VULGARIS POLLEN, BRASSICA NAPUS SUBSP. NAPUS POLLEN, CALLUNA VULGARIS POLLEN, CHENOPODIUM BONUS-HENRICUS POLLEN, PLANTAGO MAJOR POLLEN, RANUNCULUS BULBOSUS POLLEN, URTICA DIOICA POLLEN
Route / form: Not reported
Status: Unapproved homeopathic label · US
Record type: Homeopathic label record
Preserved context: See the local medicine record for current source-backed regulatory and study context.
Open local regulatory record →A catalog record is not, by itself, an efficacy claim.Registry Results
Registry-submitted primary-outcome values are shown with exact local provenance. The service does not infer efficacy, effect direction or a treatment recommendation from these unreviewed values.
The registry has not posted a Results section for these records. A protocol does not show whether the intervention worked.No registry Results section is pinned in this frozen report snapshot.
A registration describes what was planned. It does not show whether the intervention worked.
Safety
The linked evidence is source-reported and remains candidate-only. Contraindications and patient-specific guidance are not yet validated.
Latest additions
The articles, studies and medicine records shown here are fixed to one dated snapshot. Their source identifiers and links were checked, but the platform has not turned registry entries into clinical conclusions.
This condition is normalized as D008881 using Medical Subject Headings 2026.
2,859 source identifiers verified · snapshot record 1520768805c4...Dates are derived from this report's immutable package pins. A failed refresh does not replace the last good report.
Limits
Showing 12 of 1,409 frozen records. Browse the complete set →
Showing 12 of 1,072 frozen records. Browse the complete set →